.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,169,750

« Back to Dashboard

Details for Patent: 7,169,750

Title:Methods to mobilize progenitor/stem cells
Abstract: Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z' (1) or pharmaceutically acceptable salt thereof wherein Z is of the formula ##STR00001## wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1 20 atoms, Z' is of the formula --Ar(Y).sub.j; wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0 3; and "linker" represents a bond, alkylene (1 6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
Inventor(s): Bridger; Gary (Bellingham, WA), Abrams; Michael J. (Custer, WA), Henson; Geoffrey W. (Ferndale, WA), MacFarland; Ronald T. (Vancouver, CA), Calandra; Gary B. (Cresco, PA)
Assignee: Anormed, Inc. (Langley, CA)
Filing Date:Jun 05, 2003
Application Number:10/456,942
Claims:1. A method to obtain progenitor and/or stem cells, from a subject, which method comprises (a) administering to said subject a compound of the formula Z-linker-Z' (1) or pharmaceutically acceptable salt or prodrug form thereof wherein Z is of the formula ##STR00005## wherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1 20 atoms, Z' is of the formula --Ar(Y).sub.j; wherein Ar is an aromatic or heteroaromatic moiety, and each Y is independently a non-interfering substituent and j is 0 3; and "linker" represents a bond, alkylene (1 6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms; in an amount effective to mobilize said progenitor and/or stem cell population in said subject; followed by (b) harvesting said progenitor and/or stem cells.

2. The method of claim 1 wherein the compound of formula (1) is of the formula: ##STR00006## and salts and prodrug forms thereof wherein: Ring A optionally comprises a heteroatom selected from N, O and S; the dotted lines represent optional unsaturation; R1, R2 and R3 are non-interfering substituents; k is 0 4; l is 0, 1, or 2; X is unsubstituted or substituted C or N; or is O or S; Ar is the residue of an aromatic or heteroaromatic moiety; each n is independently 0 2; each R is independently H or alkyl (1 6C); j is 0 3; and each Y is independently halo, OH, SH, SO, SO.sub.2, or an organic moiety of 1 20C atoms that does not contain N wherein two such Y may be connected to form a fused ring with Ar, or is selected from the group consisting of --(CR.sub.2).sub.mCN, --(CR.sub.2).sub.mNR.sup.5.sub.2, --(CR.sub.2).sub.mNR(CR.sub.2).sub.mNRR.sup.4, --(CR.sub.2).sub.mNR(CR.sub.2).sub.mNR(CR.sub.2)mNR.sup.5.sub.2, --(CR.sub.2).sub.mCO(CR.sub.2).sub.mNR.sup.5.sub.2, --(CR.sub.2).sub.mCO(CR.sub.2).sub.mNR(CR.sub.2).sub.mNRR.sup.4, --(CR.sub.2).sub.mCO(CR.sub.2).sub.mNR(CR.sub.2).sub.mNR(CR.sub.2).sub.mN- R.sup.5.sub.2, --(CR.sub.2).sub.mNRCO(CR.sub.2).sub.mNRR.sup.4, --(CR.sub.2).sub.mNRCO(CR.sub.2).sub.mNR(CR.sub.2).sub.mNR.sup.5.sub.2, --(CR.sub.2).sub.mNRCO(CR.sub.2).sub.mNR(CR.sub.2).sub.mNR(CR.sub.2).sub.- mNR(CR.sub.2).sub.mNR.sup.5.sub.2, --CH.dbd.N--Z'', --(CR.sub.2).sub.mZ'', --NR (CR.sub.2).sub.mZ'', --(CR.sub.2).sub.mNROH, (CR.sub.2).sub.mCONROH, and (CR.sub.2).sub.mCR.dbd.NOH, wherein Z'' is an optionally substituted aromatic or heteroaromatic moiety containing 5 12 ring members; and wherein R is as defined above, each m is independently 0 4, and R.sup.4 and each R.sup.5 is independently H, alkyl (1 6C), alkenyl (1 6C), alkynyl (1 6C), or acyl (1 6C), each optionally substituted by one or more nonaromatic, nonheterocyclic substituent(s), and wherein two R.sup.5 may be connected to form a cyclic amine, optionally containing one or more additional heteroatoms selected from N, O, and S.

3. The method of claim 2 wherein ring E is coupled to the remainder of the molecule at position 2.

4. The method of claim 3 wherein R.sup.2 and R.sup.3 taken together form a benzo substituent.

5. The method of claim 4 wherein X is N and ring E comprises a pi bond coupled to one N.

6. The method of claim 2 wherein ring A is saturated and l is 1.

7. The method of claim 6 wherein k is 0 1.

8. The method of claim 7 wherein the ring system which includes A is tetrahydroquinoline or a substituted form thereof.

9. The method of claim 2 wherein one of (CR.sub.2).sup.a.sub.n and (CR.sub.2).sup.b.sub.n is CH.sub.2 and the other is a bond.

10. The method of claim 9 wherein (CR.sub.2).sup.a.sub.n is a bond and (CR.sub.2).sup.b.sub.n is CH.sub.2.

11. The method of claim 2 wherein at least one Y is --CH.sub.2NH.sub.2.

12. The method of claim 2 wherein Ar is the residue of benzene, benzimazole, benzothiazole, imidazole, oxazole, benztriazole, thiazole, pyridine, or pyrimidine.

13. The method of claim 1 wherein formula (1) is in the form of its acid addition salt.

14. The method of claim 13 wherein the acid addition salt is a hydrochloride.

15. The method of claim 1 wherein the subject is a healthy stem cell donor.

16. The method of claim 1 wherein the compound is administered to said subject by an intravenous or subcutaneous route.

17. The method of claim 1 wherein the compound of formula (1) is administered to said subject in a dosage range of about 0.1 .mu.g/kg 5 mg/kg of body weight.

18. The method of claim 1 which further comprises administering macrophage inflammatory protein to said subject.

19. The method of claim 1 which further includes the step of administering G-CSF to said subject prior to performing the method.

20. The method of claim 1 wherein the subject is human.

21. The method of claim 1 wherein the harvesting is by apheresis.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc